NO333015B1 - Melatonin for anvendelse for a lindre svekket kognisjon og/eller svekket hukommelse, samt en kombinasjon for samme formal - Google Patents

Melatonin for anvendelse for a lindre svekket kognisjon og/eller svekket hukommelse, samt en kombinasjon for samme formal

Info

Publication number: NO333015B1
Authority: NO; Norway
Prior art keywords: melatonin; drug; amount; range; nicotine
Prior art date: 2003-04-29

Application number

NO20055531A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055531L (no

Inventor

Moshe Laudon

Nava Zisapel

Original Assignee

Neurim Pharma 1991

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-29

Filing date

2005-11-23

Publication date

2013-02-18

2005-11-23 Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991

2005-11-23 Publication of NO20055531L publication Critical patent/NO20055531L/no

2013-02-18 Publication of NO333015B1 publication Critical patent/NO333015B1/no

Links

DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 153
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 152
229960003987 melatonin Drugs 0.000 title claims abstract description 152
230000001771 impaired effect Effects 0.000 title claims abstract description 26
230000015654 memory Effects 0.000 title claims abstract description 17
230000019771 cognition Effects 0.000 title claims abstract description 14
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 70
229960002715 nicotine Drugs 0.000 claims abstract description 70
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 70
239000003814 drug Substances 0.000 claims abstract description 67
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract description 40
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract description 40
239000004480 active ingredient Substances 0.000 claims abstract description 20
238000002670 nicotine replacement therapy Methods 0.000 claims abstract description 19
239000000018 receptor agonist Substances 0.000 claims abstract description 12
229940044601 receptor agonist Drugs 0.000 claims abstract description 12
229940079593 drug Drugs 0.000 claims description 57
238000013270 controlled release Methods 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 23
238000009472 formulation Methods 0.000 claims description 14
230000002459 sustained effect Effects 0.000 claims description 10
238000013265 extended release Methods 0.000 claims description 9
238000013268 sustained release Methods 0.000 claims description 9
239000002671 adjuvant Substances 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 5
230000000694 effects Effects 0.000 abstract description 23
238000011282 treatment Methods 0.000 abstract description 22
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 21
206010022437 insomnia Diseases 0.000 abstract description 21
230000003860 sleep quality Effects 0.000 abstract description 11
239000003795 chemical substances by application Substances 0.000 abstract description 8
239000002552 dosage form Substances 0.000 abstract description 3
239000004615 ingredient Substances 0.000 abstract description 3
230000002411 adverse Effects 0.000 abstract description 2
239000005557 antagonist Substances 0.000 abstract 2
230000001193 melatoninergic effect Effects 0.000 abstract 1
230000007958 sleep Effects 0.000 description 21
239000000902 placebo Substances 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
230000000391 smoking effect Effects 0.000 description 12
230000004913 activation Effects 0.000 description 11
230000005586 smoking cessation Effects 0.000 description 11
238000003756 stirring Methods 0.000 description 11
239000000853 adhesive Substances 0.000 description 10
230000001070 adhesive effect Effects 0.000 description 10
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
238000013461 design Methods 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
239000003826 tablet Substances 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
230000003920 cognitive function Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229940088597 hormone Drugs 0.000 description 6
239000005556 hormone Substances 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
229960004373 acetylcholine Drugs 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229960000890 hydrocortisone Drugs 0.000 description 5
230000000147 hypnotic effect Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
208000024827 Alzheimer disease Diseases 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000003542 behavioural effect Effects 0.000 description 4
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 4
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000000422 nocturnal effect Effects 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
206010009900 Colitis ulcerative Diseases 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
102000001419 Melatonin receptor Human genes 0.000 description 3
108050009605 Melatonin receptor Proteins 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
241000208125 Nicotiana Species 0.000 description 3
235000002637 Nicotiana tabacum Nutrition 0.000 description 3
241000700159 Rattus Species 0.000 description 3
201000006704 Ulcerative Colitis Diseases 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229960001058 bupropion Drugs 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
235000019504 cigarettes Nutrition 0.000 description 3
230000001149 cognitive effect Effects 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
208000019116 sleep disease Diseases 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
102000009660 Cholinergic Receptors Human genes 0.000 description 2
108010009685 Cholinergic Receptors Proteins 0.000 description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000003281 allosteric effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
230000008021 deposition Effects 0.000 description 2
229960003980 galantamine Drugs 0.000 description 2
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
210000004560 pineal gland Anatomy 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
102100033639 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
206010027590 Middle insomnia Diseases 0.000 description 1
UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010062519 Poor quality sleep Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
208000010340 Sleep Deprivation Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000002060 circadian Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003931 cognitive performance Effects 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
230000002650 habitual effect Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000007087 memory ability Effects 0.000 description 1
230000005056 memory consolidation Effects 0.000 description 1
230000006386 memory function Effects 0.000 description 1
230000007334 memory performance Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000012254 powdered material Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001003 psychopharmacologic effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
208000012672 seasonal affective disease Diseases 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000004620 sleep latency Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000003936 working memory Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20055531A 2003-04-29 2005-11-23 Melatonin for anvendelse for a lindre svekket kognisjon og/eller svekket hukommelse, samt en kombinasjon for samme formal NO333015B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL155666A IL155666A (en)	2003-04-29	2003-04-29	Insomnia treatment
PCT/IL2004/000330 WO2004096118A2 (en)	2003-04-29	2004-04-15	Composition for improving cognition and memory

Publications (2)

Publication Number	Publication Date
NO20055531L NO20055531L (no)	2005-11-23
NO333015B1 true NO333015B1 (no)	2013-02-18

Family

ID=33397641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055531A NO333015B1 (no)	2003-04-29	2005-11-23	Melatonin for anvendelse for a lindre svekket kognisjon og/eller svekket hukommelse, samt en kombinasjon for samme formal

Country Status (28)

Country	Link
US (2)	US8859593B2 (de)
EP (1)	EP1620058B1 (de)
JP (2)	JP4981440B2 (de)
KR (1)	KR101136885B1 (de)
CN (1)	CN1787820B (de)
AR (1)	AR048370A1 (de)
AT (1)	ATE539746T1 (de)
BR (1)	BRPI0409935A (de)
CA (1)	CA2521182C (de)
CL (1)	CL2004000877A1 (de)
CY (1)	CY1112689T1 (de)
DK (1)	DK1620058T3 (de)
EA (1)	EA008768B1 (de)
ES (1)	ES2380364T3 (de)
IL (1)	IL155666A (de)
IS (1)	IS8090A (de)
MX (1)	MXPA05011590A (de)
NO (1)	NO333015B1 (de)
NZ (1)	NZ542724A (de)
PE (1)	PE20050144A1 (de)
PL (1)	PL1620058T3 (de)
PT (1)	PT1620058E (de)
SI (1)	SI1620058T1 (de)
TW (1)	TWI340037B (de)
UA (1)	UA87980C2 (de)
UY (1)	UY28296A1 (de)
WO (1)	WO2004096118A2 (de)
ZA (1)	ZA200509508B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL155666A (en) *	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment
JP4993900B2 (ja) *	2005-11-28	2012-08-08	国立大学法人東京医科歯科大学	記憶障害抑制剤
US8372876B2 (en) *	2007-03-06	2013-02-12	The University Of Houston System	Method for improving memory in mammals
US8940326B2 (en)	2007-03-19	2015-01-27	Vita Sciences Llc	Transdermal patch and method for delivery of vitamin B12
WO2008128095A1 (en)	2007-04-12	2008-10-23	Regents Of The University Of Minnesota	Ischemia/reperfusion protection compositions and methods of using
WO2013112951A2 (en)	2012-01-26	2013-08-01	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
US11918557B2 (en)	2012-01-26	2024-03-05	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
KR102148990B1 (ko) *	2012-12-18	2020-08-27	반다 파마슈티칼즈, 인코퍼레이티드.	일주기 리듬 장애의 치료
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
US11090285B2 (en)	2013-11-12	2021-08-17	Vanda Pharmaceuticals Inc	Treatment of circadian rhythm disorders
CN107810003B (zh) *	2015-02-04	2022-05-03	索尔约瑟法梅内德斯公司	包含瓦伦托宁的透皮治疗系统及其作为药物的应用
US10307398B2 (en)	2016-09-20	2019-06-04	Regents Of The University Of Minnesota	Resuscitation composition and methods of making and using
KR102499141B1 (ko) *	2016-10-31	2023-02-13	신신제약 주식회사	수면장애 치료용 경피흡수제제
US10849856B2 (en)	2016-10-31	2020-12-01	Neurim Pharmaceuticals Ltd.	Melatonin mini-tablets and method of manufacturing the same
JP6830156B2 (ja)	2016-10-31	2021-02-17	ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ．	メラトニンミニタブレットおよびその製造方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US468017A (en) *		1892-02-02		Lock-case
US4506080A (en) *	1983-07-01	1985-03-19	Nestec S. A.	Preparation of serotonine and derivatives
US4765985A (en)	1985-03-05	1988-08-23	Ciba-Geigy Corporation	Devices and methods for treating memory impairment
US4965074A (en)	1985-03-05	1990-10-23	Ciba-Geigy Corporation	Method of treating memory impairment
US4680172A (en)	1985-03-05	1987-07-14	Ciba-Geigy Corporation	Devices and methods for treating memory impairment
DE3775830D1 (de)	1986-06-13	1992-02-20	Alza Corp	Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
DE3645036A1 (de)	1986-11-18	1989-01-05	Forschungsgesellschaft Rauchen	Nikotinhaltiges mittel
CA2116036A1 (en)	1991-10-18	1993-04-29	F. Eugene Yates	Device for the transdermal administration of melatonin
EP0620849B1 (de) *	1992-01-07	2003-06-25	Elan Pharmaceuticals, Inc.	Transgene tiermodelle fur alzheimer-krankheit
DE69303919T2 (de)	1992-04-07	1997-01-30	Neurim Pharma 1991	Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
US5449683A (en) *	1992-10-01	1995-09-12	Massachussetts Institute Of Technology	Methods of inducing sleep using melatonin
GB9310412D0 (en)	1993-05-20	1993-07-07	Danbiosyst Uk	Nasal nicotine system
DE69422925T2 (de) *	1993-07-09	2000-08-17	Cygnus, Inc.	Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten
CA2187023A1 (en)	1994-04-13	1995-10-26	Steven Andrew Giannos	Temporally controlled drug delivery systems
US6017887A (en)	1995-01-06	2000-01-25	Sibia Neurosciences, Inc.	Peptide, peptide analog and amino acid analog protease inhibitors
MD1716C2 (ro)	1995-02-01	2002-02-28	Neurim Pharmaceuticals (1991) Ltd.	Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
US5696115A (en)	1995-04-21	1997-12-09	Eli Lilly And Company	Method for treating nicotine withdrawal
US5700828A (en)	1995-12-07	1997-12-23	Life Resuscitation Technologies, Inc.	Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
PT906089E (pt)	1996-05-13	2004-01-30	Novartis Consumer Health Sa	Sistema de administracao bucal
FR2762993B1 (fr) *	1997-05-06	1999-08-13	Inst Rech Biolog Sa	Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
JP2002500652A (ja) *	1997-05-30	2002-01-08	ニューロサーアチ・アクティーゼルスカブ	スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
US6274615B1 (en) *	1998-03-25	2001-08-14	South Alabama Medical Science Foundation	Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
US6353015B1 (en)	1998-08-26	2002-03-05	St. Elizabeth's Medical Center	Method of treating neurodegenerative disorders
RU2134108C1 (ru)	1998-10-06	1999-08-10	Заславская Рина Михайловна	Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) *	1999-02-02	2002-08-02	Synthelabo	Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
NZ513208A (en) *	1999-02-05	2003-05-30	Cipla Ltd	Topical sprays comprising a film forming composition
US6353051B1 (en)	1999-03-10	2002-03-05	E. I. Du Pont De Nemours And Company	Top coating for synthetic leathers
MXPA02005783A (es)	2000-01-05	2003-10-14	Neurim Pharma 1991	Metodo y formulacion para el tratamiento de la resistencia a los antihipertensivos y otras afecciones asociadas.
EP1311272B1 (de) *	2000-03-03	2006-11-22	Eisai Co., Ltd.	Neue methoden unter verwendung von cholinesteraseinhibitoren
DE10013712A1 (de)	2000-03-20	2001-09-27	Nutrinova Gmbh	Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
US6486172B2 (en) *	2000-08-18	2002-11-26	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
EP1372392A4 (de)	2001-03-26	2004-06-23	Smithkline Beecham Corp	Nikotinhaltige orale arzneiform
US7766013B2 (en)	2001-06-05	2010-08-03	Alexza Pharmaceuticals, Inc.	Aerosol generating method and device
EP1304048B1 (de) *	2001-10-22	2004-09-22	Ivo Pera	Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit
US7113651B2 (en)	2002-11-20	2006-09-26	Dmetrix, Inc.	Multi-spectral miniature microscope array
IL155666A (en) *	2003-04-29	2013-12-31	Neurim Pharma 1991	Insomnia treatment

2003
- 2003-04-29 IL IL155666A patent/IL155666A/en active IP Right Grant
2004
- 2004-04-15 AT AT04727667T patent/ATE539746T1/de active
- 2004-04-15 PL PL04727667T patent/PL1620058T3/pl unknown
- 2004-04-15 JP JP2006507610A patent/JP4981440B2/ja not_active Expired - Lifetime
- 2004-04-15 CA CA2521182A patent/CA2521182C/en not_active Expired - Lifetime
- 2004-04-15 WO PCT/IL2004/000330 patent/WO2004096118A2/en not_active Ceased
- 2004-04-15 PT PT04727667T patent/PT1620058E/pt unknown
- 2004-04-15 EA EA200501666A patent/EA008768B1/ru unknown
- 2004-04-15 SI SI200431850T patent/SI1620058T1/sl unknown
- 2004-04-15 DK DK04727667.0T patent/DK1620058T3/da active
- 2004-04-15 BR BRPI0409935-4A patent/BRPI0409935A/pt not_active Application Discontinuation
- 2004-04-15 KR KR1020057020416A patent/KR101136885B1/ko not_active Expired - Lifetime
- 2004-04-15 US US10/555,011 patent/US8859593B2/en active Active
- 2004-04-15 NZ NZ542724A patent/NZ542724A/en not_active IP Right Cessation
- 2004-04-15 EP EP04727667A patent/EP1620058B1/de not_active Expired - Lifetime
- 2004-04-15 MX MXPA05011590A patent/MXPA05011590A/es active IP Right Grant
- 2004-04-15 ES ES04727667T patent/ES2380364T3/es not_active Expired - Lifetime
- 2004-04-15 UA UAA200511154A patent/UA87980C2/ru unknown
- 2004-04-15 CN CN2004800113428A patent/CN1787820B/zh not_active Expired - Lifetime
- 2004-04-22 AR ARP040101363A patent/AR048370A1/es unknown
- 2004-04-26 CL CL200400877A patent/CL2004000877A1/es unknown
- 2004-04-28 PE PE2004000418A patent/PE20050144A1/es not_active Application Discontinuation
- 2004-04-28 TW TW093111816A patent/TWI340037B/zh not_active IP Right Cessation
- 2004-04-29 UY UY28296A patent/UY28296A1/es not_active Application Discontinuation
2005
- 2005-10-25 IS IS8090A patent/IS8090A/is unknown
- 2005-11-23 NO NO20055531A patent/NO333015B1/no unknown
2006
- 2006-11-24 ZA ZA200509508A patent/ZA200509508B/xx unknown
2012
- 2012-02-08 JP JP2012025361A patent/JP2012116859A/ja active Pending
- 2012-04-02 CY CY20121100327T patent/CY1112689T1/el unknown
2014
- 2014-09-10 US US14/482,275 patent/US20140378512A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ542724A (en)	2007-05-31
KR101136885B1 (ko)	2012-04-20
MXPA05011590A (es)	2006-03-08
EP1620058A4 (de)	2006-07-26
DK1620058T3 (da)	2012-05-07
IS8090A (is)	2005-10-25
JP4981440B2 (ja)	2012-07-18
JP2012116859A (ja)	2012-06-21
ES2380364T3 (es)	2012-05-11
AR048370A1 (es)	2006-04-26
TWI340037B (en)	2011-04-11
EP1620058A2 (de)	2006-02-01
ATE539746T1 (de)	2012-01-15
CA2521182C (en)	2011-05-31
WO2004096118B1 (en)	2005-12-01
IL155666A0 (en)	2004-09-27
CN1787820B (zh)	2010-05-05
CY1112689T1 (el)	2016-02-10
PT1620058E (pt)	2012-04-13
CA2521182A1 (en)	2004-11-11
US20140378512A1 (en)	2014-12-25
WO2004096118A3 (en)	2005-10-13
US20060229340A1 (en)	2006-10-12
UY28296A1 (es)	2004-11-30
US8859593B2 (en)	2014-10-14
JP2006525317A (ja)	2006-11-09
CN1787820A (zh)	2006-06-14
HK1087635A1 (zh)	2006-10-20
PE20050144A1 (es)	2005-05-12
SI1620058T1 (sl)	2012-05-31
UA87980C2 (ru)	2009-09-10
EP1620058B1 (de)	2012-01-04
CL2004000877A1 (es)	2005-01-07
PL1620058T3 (pl)	2012-07-31
KR20060005402A (ko)	2006-01-17
EA200501666A1 (ru)	2006-06-30
NO20055531L (no)	2005-11-23
ZA200509508B (en)	2006-11-29
EA008768B1 (ru)	2007-08-31
WO2004096118A2 (en)	2004-11-11
TW200501948A (en)	2005-01-16
BRPI0409935A (pt)	2006-04-25
IL155666A (en)	2013-12-31

Publication	Publication Date	Title
US20140378512A1 (en)	2014-12-25	Composition for improving cognition and memory
Dujovne et al.	2001	Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia
Priano et al.	2006	Transdermal treatment options for neurological disorders: impact on the elderly
KR20080071581A (ko)	2008-08-04	경피용 치료학적 시스템
JP6957455B2 (ja)	2021-11-02	ベータ細胞の複製及び／または生存の亢進
Kong et al.	2008	Melatonin induces Akt phosphorylation through melatonin receptor-and PI3K-dependent pathways in primary astrocytes
US9119846B2 (en)	2015-09-01	Method and composition for enhancing cognition in alzheimer's patients
Heckman et al.	2017	From age-related cognitive decline to Alzheimer’s disease: a translational overview of the potential role for phosphodiesterases
Kubota et al.	2001	Pregabalin enhances nonrapid eye movement sleep
NO973715L (no)	1997-08-12	Transdermal formulering
Jus et al.	1978	Deanol, lithium and placebo in the treatment of tardive dyskinesia: a double-blind crossover study
Carlsson et al.	1986	A central serotonin receptor agonist, 8‐hydroxy‐2‐(di‐n‐propylamino) tetralin, has different effects on prolactin secretion in male and female rats
AU2005234682B2 (en)	2008-06-26	Composition for Improving Cognition and Memory
Reichmann	2006	Budipine in Parkinson's tremor
HK1087635B (en)	2010-12-03	Composition for improving cognition and memory
Howe et al.	2003	Venlafaxine-induced delirium
Mahmoud et al.	2022	Tramadol as an analgesic
Lal et al.	1981	Effect of choline on central dopaminergic function in normal subjects
KR20100063320A (ko)	2010-06-11	시탈로프람의 치료학적 혈중농도를 유지할 수 있는 경피흡수제형
Wiegand et al.	1999	Yohimbine hydrochloride in erectile dysfunction: Action on symptomatology, sleep, and nocturnal penile tumescence (NPT)
Nowakowska et al.	1999	The influence of MAO inhibitors on cognitive functions in rats
AU2011236053B2 (en)	2014-06-26	Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
Bray	2018	Ventral Hippocampal Corticosterone Mediates Accumbal Shell Dopamine Output: Potential Link between Stress and Incentive Salience in Control Conditions and in Protracted Amphetamine Withdrawal
Doorschot et al.	1999	Concomitant use of mirtazapine and risperidone: A pilot study
Yuri	1990	Broncho-pulmonary pharmacology of lipomodulators